Javascript verkar inte påslaget? - Vissa delar av Lunds universitets webbplats fungerar inte optimalt utan javascript, kontrollera din webbläsares inställningar.
Du är här

Antibody microarray-based oncoproteomics

Publiceringsår: 2006
Språk: Engelska
Sidor: 833-838
Publikation/Tidskrift/Serie: Expert Opinion on Biological Therapy
Volym: 6
Nummer: 8
Dokumenttyp: Artikel i tidskrift
Förlag: Ashley Publications


The driving force behind oncoproteomics is the belief that certain protein signatures or patterns exist that are associated with a particular malignancy. if so, the correlation of clinical parameters with defined protein expression patterns would allow us to predict disease progression and perhaps even postulate improved therapeutic modalities. The technological challenges to achieve these goals are significant, as the human proteome is not defined. No general methodological approach exists today, and human cancer can, furthermore, be divided into several disease subgroups. One potential solution to finding cancer-associated protein signatures is the emerging technology of affinity proteomics. This approach addresses some of the shortcomings of traditional proteomics and combines it with the power of microarrays. The present review focuses on the role of antibody microarrays in oncoproteomics and its potential to provide a truly proteome-wide analytical approach.


  • Immunology in the medical area
  • recombinant
  • antibody
  • proteome analysis
  • microarray
  • affinity proteomics
  • cancer


  • ISSN: 1471-2598

Box 117, 221 00 LUND
Telefon 046-222 00 00 (växel)
Telefax 046-222 47 20
lu [at]

Fakturaadress: Box 188, 221 00 LUND
Organisationsnummer: 202100-3211
Om webbplatsen